TSVT Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 0.25%, SMA50 6.5%, SMA200 23.03%). The stock’s 14-day RSI is 72.25 (overbought), while the ATR of 0.03 points to tighter daily ranges. The stock remains hovering near 52-week lows, trading -5.66% below its high and over 118.34% above its low.

The latest quarter delivered EPS of $0.01. The next quarter is forecast at $nan. Next year's EPS is expected at $47.55. 2seventy bio, Inc. earnings surprise history is a mixed track record. The quarter that ended May 07, 2025, missed forecasts by -105.88%. The prior quarter beat by 34.78%. Over the last six quarters, Apple has recorded several small beats. These include 54.17% in May 01, 2024.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

The stock is currently mid-range between its 52-week high and low $2.29 and $5.30. With a market capitalization of about $266.14 million, 2seventy bio, Inc. is classified as a micro-cap and shows market-like volatility (beta ~1.05). Key stats such as the average daily volume over the past year has been around 1.46 million shares, in line with its 52-week average. Headquartered in Cambridge, MA, 2seventy bio, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO William D. Baird III,, the company employs approximately 65 people and listed since November 03, 2021. 2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States.

2seventy bio, Inc. has 53.23 million shares outstanding. The public float is 41.98 million shares, elevated short interest at 7.51% of float. This equals 3.78 million shares. The short ratio is 3.25 days. Institutional investors hold 88.07% of the float. Insiders own 6.44%. Kynam Capital Management, LP holds 5.14 million shares, Casdin Capital, LLC has 2.00 million shares and Leschly Nick has 1.23 million shares.

2seventy bio, Inc. (NASDAQ:TSVT) shares are up 70.07% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows 2seventy bio, Inc. trading at a premium to the broader market with a P/E of -13.93. Analyst sentiment is cautious, with the majority of ratings in Equal-Weight territory and a mean price target of $22.30, suggesting 346.0% upside.

Our AI price prediction model suggests that 2seventy bio, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 3-Month Outlook: Projected rise of 104.6%, reaching $10.23 by August 20, 2025, with a range of $10.02 to $10.73. 1-Year Outlook: Projected gain of 272.2%, with price at $18.61 by May 22, 2026, within a range of $5.97 to $25.70.

2seventy bio, Inc. trades at a P/E ratio of -13.93, slightly below the S&P 500 average, with a price-to-sales ratio of 10.29 and a price-to-book ratio of 1.24 suggesting the stock is closer to book value. The P/FCF stands at -13.02, also above market averages.